223 related articles for article (PubMed ID: 31277771)
1. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.
Patel HD; Gupta M; Joice GA; Srivastava A; Alam R; Allaf ME; Pierorazio PM
Eur Urol Oncol; 2019 Jul; 2(4):343-348. PubMed ID: 31277771
[TBL] [Abstract][Full Text] [Related]
2. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.
Amin MB; Corless CL; Renshaw AA; Tickoo SK; Kubus J; Schultz DS
Am J Surg Pathol; 1997 Jun; 21(6):621-35. PubMed ID: 9199639
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
Neuzillet Y; Tillou X; Mathieu R; Long JA; Gigante M; Paparel P; Poissonnier L; Baumert H; Escudier B; Lang H; Rioux-Leclercq N; Bigot P; Bernhard JC; Albiges L; Bastien L; Petit J; Saint F; Bruyere F; Boutin JM; Brichart N; Karam G; Branchereau J; Ferriere JM; Wallerand H; Barbet S; Elkentaoui H; Hubert J; Feuillu B; Theveniaud PE; Villers A; Zini L; Descazeaux A; Roupret M; Barrou B; Fehri K; Lebret T; Tostain J; Terrier JE; Terrier N; Martin L; Dugardin F; Galliot I; Staerman F; Azemar MD; Irani J; Tisserand B; Timsit MO; Sallusto F; Rischmann P; Guy L; Valeri A; Deruelle C; Azzouzi AR; Chautard D; Mejean A; Salomon L; Rigaud J; Pfister C; Soulié M; Kleinclauss F; Badet L; Patard JJ; ;
Eur Urol; 2011 Aug; 60(2):366-73. PubMed ID: 21377780
[TBL] [Abstract][Full Text] [Related]
4. Renal cell cancer stage migration: analysis of the National Cancer Data Base.
Kane CJ; Mallin K; Ritchey J; Cooperberg MR; Carroll PR
Cancer; 2008 Jul; 113(1):78-83. PubMed ID: 18491376
[TBL] [Abstract][Full Text] [Related]
5. Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: Evidence in support of expanding the definition of stage IV kidney cancer.
Srivastava A; Rivera-Núñez Z; Kim S; Sterling J; Farber NJ; Radadia KD; Patel HV; Modi PK; Goyal S; Parikh R; Mayer TM; Saraiya B; Sadimin ET; Weiss RE; Kim IY; Elsamra SE; Jang TL; Singer EA
Cancer; 2020 Jul; 126(13):2991-3001. PubMed ID: 32329899
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?
Brookman-May SD; May M; Wolff I; Zigeuner R; Hutterer GC; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Feciche B; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Zastrow S; Wirth M; Sountoulides P; Shariat S; Waidelich R; Stief C; Gunia S; ;
Eur Urol; 2015 May; 67(5):943-51. PubMed ID: 25684695
[TBL] [Abstract][Full Text] [Related]
7. The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.
Bhindi B; Thompson RH; Lohse CM; Mason RJ; Frank I; Costello BA; Potretzke AM; Hartman RP; Potretzke TA; Boorjian SA; Cheville JC; Leibovich BC
Eur Urol; 2018 Oct; 74(4):489-497. PubMed ID: 30017400
[TBL] [Abstract][Full Text] [Related]
8. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib-II renal masses: An analysis of the national cancer data base.
Ristau BT; Handorf EA; Cahn DB; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2018 Oct; 124(19):3839-3848. PubMed ID: 30207380
[TBL] [Abstract][Full Text] [Related]
9. Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?
Capitanio U; Stewart GD; Klatte T; Akdogan B; Roscigno M; Marszalek M; Dell'Oglio P; Zaffuto E; Rodriguez Faba O; Salagierski M; Lingard J; Carini M; Ouzaid I; Mir MC; Montorsi F; Da Pozzo LF; Stief C; Minervini A; Brookman-May SD
Eur Urol Focus; 2018 Dec; 4(6):972-977. PubMed ID: 28753867
[TBL] [Abstract][Full Text] [Related]
10. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
11. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes.
Simone G; Tuderti G; Ferriero M; Papalia R; Misuraca L; Minisola F; Costantini M; Mastroianni R; Sentinelli S; Guaglianone S; Gallucci M
Eur J Surg Oncol; 2016 Nov; 42(11):1744-1750. PubMed ID: 27593224
[TBL] [Abstract][Full Text] [Related]
12. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.
Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC
Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296
[TBL] [Abstract][Full Text] [Related]
13. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.
Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS
Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of renicapsular involvement in Stages I and II renal cell carcinoma from the morphological and prognostic point of view.
May M; Brookman-Amissah S; Roigas J; Gilfrich CP; Pflanz S; Hoschke B; Gunia S
Urol Oncol; 2010; 28(3):274-9. PubMed ID: 18805709
[TBL] [Abstract][Full Text] [Related]
15. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
16. A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis.
Sun M; Abdollah F; Bianchi M; Trinh QD; Jeldres C; Tian Z; Shariat SF; Widmer H; Zorn K; Menon M; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2011 Dec; 60(6):1152-9. PubMed ID: 21868147
[TBL] [Abstract][Full Text] [Related]
17. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study.
Lawson KA; Saarela O; Abouassaly R; Kim SP; Breau RH; Finelli A
Eur Urol; 2017 Sep; 72(3):379-386. PubMed ID: 28511884
[TBL] [Abstract][Full Text] [Related]
19. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
[TBL] [Abstract][Full Text] [Related]
20. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
